The Ca2+-activated K+ channel of intermediate conductance: A possible target for immune suppression

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 6, 2002, Pages 623-636

  Jensen, B S ^a   Hertz, M ^b   Christophersen, P ^a   Madsen, L S ^a,c  

^a NEUROSEARCH A S   (Denmark)

^b Pharmexa AS   (Denmark)

^c Poseidon Pharmaceuticals A/S   (Denmark)

Author keywords

Clotrimazole; IK; Immune suppression; Kv1.3; Multiple sclerosis; T cells

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALMODULIN; CETIEDIL; CHARYBDOTOXIN; CLOTRIMAZOLE; CYCLOSPORIN A; ECONAZOLE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; KETOCONAZOLE; LEFLUNOMIDE; METHOTREXATE; MICONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; POTASSIUM CHANNEL BLOCKING AGENT; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS; TRAM 34; UCL 1559; UCL 1608; UNCLASSIFIED DRUG; UNINDEXED DRUG; CALCIUM CHANNEL BLOCKING AGENT; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNA3 PROTEIN, HUMAN; KCNA3 PROTEIN, MOUSE; KCNA3 PROTEIN, RAT; KCNN4 PROTEIN, HUMAN; KCNN4 PROTEIN, MOUSE; PEPTIDE; POTASSIUM; POTASSIUM CHANNEL KV1.3; VENOM; VOLTAGE GATED POTASSIUM CHANNEL;

ABDOMINAL PAIN; AUTOIMMUNE DISEASE; BIRTH DEFECT; BLOOD CELL; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE POTENTIAL; CONVULSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG POTENCY; DRUG STRUCTURE; DYSLIPIDEMIA; ENTERITIS; EPITHELIUM; GLUCOSE INTOLERANCE; HAIR LOSS; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LYMPHOCYTE PROLIFERATION; MEMBRANE CHANNEL; MOUSE; MULTIPLE SCLEROSIS; MUSCLE TISSUE; NEPHROTOXICITY; NERVOUS TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PHOTOALLERGY; POTASSIUM CONDUCTANCE; RAT; REVIEW; RHEUMATOID ARTHRITIS; STOMACH PAIN; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; THORAX PAIN; ULCER; ANIMAL; BIOLOGICAL MODEL; CHANNEL GATING; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ION TRANSPORT; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION;

ANIMALS; AUTOIMMUNE DISEASES; CALCIUM; CALCIUM CHANNEL BLOCKERS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; ION CHANNEL GATING; ION TRANSPORT; KV1.3 POTASSIUM CHANNEL; LYMPHOCYTE ACTIVATION; MICE; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; PEPTIDES; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN CONFORMATION; RATS; T-LYMPHOCYTES; VENOMS;

EID: 0036927428     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.6.623     Document Type: Review

References (97)

1. GOODNOW CC: Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad Sci. USA (1996) 93:2264-2271.
2. O'GARRA A, STEINMAN I, GIJBEL SK: CD4+ T cell subsets in autoimmunity. Curr. Opin. Immunol. (1997) 9:872-883.
3. LAFFERTY KJ: A contemporary view of transplantation tolerance: an immunologist's perspective. Clin. Transplant. (1994) 8:181-187.
4. ROSENBERG AS, SINGER A: Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Ann. Rev. Immunol. (1992) 10:333-358.
5. CLIPSTONE NA, CRABTREE GR: Identification of calcineurin as a key signalling enzyme in T lymphocyte activation. Nature (1992) 357:695-697.
6. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125-1127.
7. CALABRESE LH: Anakinra treatment of patients with rheumatoid arthritis. Ann. Pharmacother. (2002) 36:1204-1209.
8. LOGSDON NJ, KANG J, TOGO JA et al.: A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol, Chem. (1997) 272:32723-32726.
9. CHANDY KG, WILLIAMS CB, SPENCER RH, AGUILAR BA, GHANSHANI S, TEMPEL BL, GUTMAN GA: A family of three mouse potassium channel genes with intronless coding regions. Science (1990) 247:943-975.
10. VERGARA C, LATORRE R, MARRION NV, ADELMAN JP: Calcium-activated potassium channels. Curr. Opin. Neurobiol. (1998) 8:321-329.
11. ISHII TM, SILVIA C, HIRSCHBERG B, BOND CT, ADELMAN JP, MAYLIE J: A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. USA (1997) 94:11651-11656.
12. + channel. Am. J. Physiol. (1998) 275:C848-C856.
13. FANGER CM, GHANSHANI S, LOGSDON NJ et al.: Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J. Biol. Chem. (1999) 274(9):5746-5754.
14. KHANNA R, CHANG MC, JOINER WJ, KACZMAREK LK, SCHLICHTER LC: hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation. J. Biol. Chem. (1999) 274(21):14838-14349.
15. + channel. Am. J. Physiol. (1996) 271(5 Pt 1):L775-L784.
16. + conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J. Clin. Invest. (1997) 100:3111-3120.
17. BRUGNARA. C, GEE B, ARMSBY CC, KURTH S et al.: Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J. Clin. Invest. (1996) 97:1227-1234.
18. GRISSMER S, NGUYEN AN, CAHALAN MD: Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J. Gen. Physiol. (1993) 102:601-630.
19. JOINER WJ, WANG LY, TANG MD, KACZMAREK LK: hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl. Acad. Sci. USA (1997) 94:11013-11018.
20. GHANSHANI S, WULFF H, MILLER MJ, ROHM H, NEBEN A, GUTMAN GA: Upregulation of the IKCa1 potassium channel during T cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. (2000) 275(47):37137-37149.
21. + channel of intermediate conductance: a molecular target for novel treatments? Curr. Drug Targets (2001) 2:401-422.
22. BOETTGER MK, TILL S, CHEN MX et al.: Calcium-activated potassium channel SK1- and IK1-like immunoreactivity in injured human sensory neurons and its regulation by neurotrophic factors. Brain (2002) 125(Pt 2):252-263.
23. + channel, IKCa1: a potential immunosuppressant. Proc. Natl. Acad. Sci. USA (2000) 97(14):8151-8156.
24. BURGESS GM, CLARET M, JENKINSON DH: Effects of quinine and apamin on the calcium-dependent potassium permeability of mammalian hepatocytes and red cell. J. Physiol. (1981) 317:67-90.
25. + channel. J. Biol. Chem. (1986) 261(31):14607-14613.
26. CASTLE NA, STRONG PN: Identification of two toxins from scorpion (Leiurus quinquestriatus) venom, which block distinct classes of calcium-activated potassium channel. FEBS Lett. (1986) 209(1):117-121.
27. 2+ and block by charybdotoxin. Am. J. Physiol. (1990) 258(6 Pt 1):L334-L342.
28. YOUNG RJ, SMITH TC, LEVINSON C: Regulatory volume decrease in Ehrlich ascites tumour cells is not mediated by a rise in intracellular calcium. Biochim Biophys Acta. (1993) 1146(1):81-86.
29. + channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. J. Membr. Biol. (1995) 147(1):71-82.
30. PENA TL, RANE SG: The fibroblast intermediate conductance K(Ca) channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family. J. Membr. Biol (1999) 172:249-257.
31. +) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA (2001) 98:13942-13947.
32. CASTLE N, CREECH C, SABATIER JM: Maurotoxin - a potent inhibitor of the intermediate conductance calcium-activated potassium channel IK1. Biophys. J. (2001) 80(1):205d. Abstract.
33. FAJLOUN Z, FERRAT G, CARLIERI E et al.: Synthesis, 1H NMR structure and activity of a three-disulfide-bridged maurotoxin analog designed to restore the consensus motif of scorpion toxins. J. Biol. Chem. (2000) 275(18):13605-13612.
34. GARCIA-CALVO M, LEONARD RJ, NOVICK J et al.: Purification, characterization and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J. Biol. Chem. (1993) 268(25):18866-18874.
35. + channels, types Kv1.1, 1.2, 1.3, 1.5 and 3.1, stably expressed in mammalian cell lines. Mol. Pharmacol. (1994) 45(6):1227-1234.
36. + channel revealed by the NMR-derived structures of scorpion toxins. Neuron (1995) 15(5):1169-1181.
37. + channels. J. Biol. Chem. (2000) 275:1201-1208.
38. CHANDY KG, CAHALAN MD, PENNINGTON MW et al.: Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon (2001) 39:1269-1276.
39. + efflux from human red blood cells. J. Membr. Biol. (1981) 59(1):57-63.
40. WOOD PG: The spontaneous activation of a potassium channel during the preparation of resealed human erythrocyte ghosts. Biochim. Biophys. Acta. (1984) 774(1):103-109.
41. BERKOWITZ LR, ORRINGER EP: Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia. Blood Cells (1982) 8(2):283-288.
42. + permeability of erythrocytes. J. Med. Chem. (2001) 44(20):3244-3253.
43. BENTON DC, ROXBURGH CJ, GANELLIN CR, SHINER MA, JENKINSON DH: Differences in the actions of some blockers of the calcium-activated potassium permeability in mammalian red cells. Br. J. Pharmacol. (1999) 126(1):169-178.
44. KAJI DM: Nifedipine inhibits calcium-activated K transport in human erythrocytes. Am. J. Physiol. (1990) 259 (2 Pt 1):C332-C339.
45. + channel of human erythrocytes. FEBS Lett. (1992) 296(2):219-221.
46. ELLORY JC, CULLIFORD SJ, SMITH PA, WOLOWYK MW, KNAUS EE: Specific inhibition of Ca-activated K channels in red cells by selected dihydropyridine derivatives. Br. J. Pharmacol. (1994) 111(3):903-905.
47. + channels by cytochrome P450 inhibitors. J. Biol. Chem. (1992) 267:11789-1179.
48. + channels from human erythrocytes. J. Membr. Biol. (1998) 165(2):133-143.
49. SPEAR KL: Novel tritylamides as potent, selective blockers of the Gardós potassium ion channel. In: Ion Channels in Drug Discovery and Development. Strategic Research Institute, New York (2002).
50. WULFF H, GUTMAN GA, CAHALAN MD, CHANDY KG: Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J. Biol. Chem. (2001) 276:32040-32045.
51. + channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 307:465-468.
52. ZINKERNAGEL RM, DOHERTY PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syrigeneic or semiallogeneic system. Nature (1974) 248(450):701-702.
53. KAPPLER JW, SKIDMORE B, WHITE J, MARRACK P: Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med. (1981) 153(5):1198-1214.
54. HEBER-KATZ E, HANSBURG D, SCHWARTZ RH: The Ia molecule of the antigen-presenting cell plays a critical role in immune response gene regulation of T cell activation. J. Mol. Cell. Immunol. (1983) 1(1):3-18.
55. GERMAIN RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. (1994) 76(2):287-299.
56. LEE K-H, HOLDORF AD, DUSTIN ML et al.: T cell receptor signalling precedes immunological synapse formation. Science (2002) 295:1539-1542.
57. SINGER AL, KORETZKY GA. Control of T cell function by positive and negative regulators. Science (2002) 296(5573):1639-1640.
58. CHANDY KG, DECOURSEY TE, CAHALAN MD, MCLAUGHLIN C, GUPTA S: Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med. (1984) 160:369-385.
59. FANGER CM, RAUER H, NEBEN AL et al.: Calcium-activated potassium channels sustain calcium signalling in T lymphocytes. Selective blockers and manipulated channel expression levels. J. Biol. Chem. (2001) 276:12249-12256.
60. RADER RK, KAHN LE, ANDERSON GD, MARTIN CL, CHINN KS, GREGORY SA: T cell activation is regulated by voltage-dependent and calcium-activated potassium channels. J. Immunol. (1996) 156:1425-1430.
61. DECOURSEY TE, CHANDY KG, GUPTA S, CAHALAN MD. Mitogen induction of ion channels in murine T lymphocytes. J. Gen. Physiol. (1987) 89:405-420.
62. LIN CS, BOLTZ RC, BLAKE JT et al.: Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. (1993) 177:637-645.
63. CAHALAN MD, WULFF H, CHANDY KG: Molecular properties and physiological roles of ion channels in the immune system. (2001) J. Clin. Immunol. 21:235-252.
64. 2+ clearance distinguish Th1 and Th2 lymphocytes. J. Immunol. (2000) 16:1153-1160.
65. KALMAN K, PENNINGTON MW, LANIGAN MD et al.: ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. (1998) 273:32697-32707.
66. 2+ in intact human T lymphocytes. Receptors Channels (1993) 1:201-215.
67. + channels in human and murine T lymphocytes. J. Gen. Physiol. (1989) 93:1061-1074.
68. BEDNAREK MA, BUGIANESI RM, LEONARD RJ, FELIX JP: Chemical synthesis and structure-function studies of margatoxin, a potent inhibitor of voltage-dependent potassium channel in human T lymphocytes. Biochem. Biophys. Res. Commun. (1994) 198:619-625.
69. NGUYEN A, KATH JC, HANSON DC et al.: Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol. Pharmacol. (1996) 50:1672-1679.
70. + channels in human T lymphocytes. Mol. Pharmacol. (1995) 48:98-104.
71. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. (2001) 166:936-944.
72. + channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis. Acta Neurol. Scand. (1994) 90:299-301.
73. + channels. Proc. Natl. Acad. Sci. USA (1999) 96:10917-10921.
74. +) channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis. Immunopharmacology (2000) 48:51-63.
75. DOS REIS GA, NOBREGA AF, PERSECHINI PM: Stage-specific distinctions in potassium channel blocker control of T-lymphocyte activation. Int. J. Immunopharmacol. (1988) 10:217-226.
76. WYBURN-MASON R: Clotrimazole in rheumatoid arthritis. Lancet (1976) 1:489.
77. WOJTULEWSKI JA, GOW PJ, WALTER J et al.: Clotrimazole in rheumatoid arthritis. Ann. Rheum. Dis. (1980) 39:469-472.
78. DENNISON WB, LOESER FR, TURNER RA et al.: A double-blind placebo-controlled trial of low dose clotrimazole in rheumatoid arthritis. J. Rheumatol. (1990) 17:1003-1007.
79. ZAMVIL S, NELSON P, TROTTER J. et al.: T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature (1985) 317:355-358.
80. MCFARLAND HF: Significance of autoreactive T cells in diseases such as multiple sclerosis using an innovative primate model. J. Clin. Invest. (1994) 94:921-922.
81. LASSMANN H, WISNIEWSKI HM: Chronic relapsing experimental allergic encephatomyelitis: clinicopathological comparison with multiple sclerosis. Arch. Neurol. (1979) 36:490-497.
82. LASSMANN H: Chronic relapsing experimental allergic encephalomyelitis: its value as an experimental model for multiple sclerosis. J. Neurol. (1983) 229:207-220.
83. BERNARD CC, CARNEGIE PR: Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J. Immunol. (1975) 114:1537-1540.
84. MADSEN LS, ANDERSSON EC, JANSSON L et al.: A humanized model for multiple sclerosis using HLA-DR2 and a human T cell receptor. Nat. Genetics (1999) 23:343-347.
85. GOVERMANN J, WOODS A, LARSON L, WEINER LP, HOOD L, ZALLER DM: Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell (1993) 72:551-560.
86. SHEVACH EM: Organ-specific autoimmunity. In: Fundamental Immunology (4th edn). Paul WE (Ed.) Lippincott-Raven Publishers, Philadelphia (1999):1093-1112.
87. NORONHA A, ARNASON B. Demyelinating diseases. In: Clinical Immunolology. Principles and Practice. Rich R (Ed.) Mosby-Year Book, St Louis (1996):1364-1376.
88. RUDICK RA, COHEN JA, WEINSTOCK-GUTTMAN B et al.: Drug therapy: management of multiple sclerosis. N. Engl. J. Med. (1997) 337:1604-1611.
89. SOLDAN SS, BERTI R, SALEM N et al.: Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. (1997) 3(12):1394-1397.
90. PERRON H, GARSON JA, BEDIN F et al.: Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc. Natl. Acad. Sci. USA (1997) 94(14):7583-7588.
91. OLDSTONE MB: Molecular mimicry and autoimmune diseases. Cell (1987) 50:819.
92. FUJINAMI RS, OLDSTONE MB: Amino acid homology between the encephalitogenic site of myelin bask protein and virus: mechanism for autoimmunity. Science (1985) 230:1043-1045.
93. WUCHERPFENNIG KW, STROMINGER JL: Molecular mimicry in cell-mediated autoimmunity: viral peptides activate human cell clones specific for myelin basic protein. Cell (1995) 80:695.
94. TROWBRIDGE IS, LESLEY J, SCHUITE R, HUMAN R, TROTTER J: Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphnode cells. Immunogenetics (1982) 28:455-458.
95. GALLATIN WM, WEISSMANN IL, BUTCHER EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature (1983) 304:30-33.
96. SCOLLAY R, SHORTMAN K: Thymocyte subpopulations: an experimental review, including flow cytometry cross-correlations between the major murine thymocyte markers. Thymus (1983) 5:245-295.
97. ANDERSSON G, MOORE NC, OWEN JJT, JENKINSON EJ: Characteristics of an in vitro system of thymocyte positive selection. J. Immunol. (1994) 153:1915-1920.